Type 2 diabetes and the polycystic ovary syndrome

Minerva Ginecologica

Volumn 56, Issue 1, 2004, Pages 41-51

  Pelusi, C ^a   Gambineri, A ^a   Pasquali, R ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Insulin resistance; PCOS; Type 2 diabetes

Indexed keywords

ANOVULATION; CARDIOVASCULAR DISEASE; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; HYPERANDROGENISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; REVIEW; RISK FACTOR;

ADULT; AGE FACTORS; AGED; BIRTH WEIGHT; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; INSULIN RESISTANCE; LIFE STYLE; MENOPAUSE; MIDDLE AGED; OBESITY; PHENOTYPE; POLYCYSTIC OVARY SYNDROME; PREVALENCE; RISK FACTORS;

EID: 1542319282     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-61.
2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
3. The Rotterdam EHSRE/ASRM Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reprod 2004;19:41-7.
4. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002;26:883-96.
5. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113-6.
6. Pasquali R, Casimirri F, Venturoli S, Paradisi R, Mattioli L, Capelli M et al. Insulin resistance in patients with polycystic ovaries: its relationship to body weight and androgen levels. Acta Endocrinol (Copenh) 1983;104:110-6.
7. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. End Rev 1997;18:774-800.
8. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999;20:535-82.
9. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986;62:904-10.
10. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075-9.
11. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995;98:33S-39S.
12. Fulghesu AM, Lanzone A, Andreani CL, Pierro E, Caruso A, Mancuso S. Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease. Fertil Steril 1995;64:703-8.
13. Moghetti P, Castello R, Negri C, Tosi F, Spiazzi GG, Brun E et al. Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 1996;81:881-6.
14. Martikainen H, Salmela P, Nuojua-Huttunen S, Perala J, Leinonen S, Knip M et al. Adrenal steroidogenesis is related to insulin in hyperandrogenic women. Fertil Steril 1996;66:564-70.
15. Stewart PM, Boutlton A, Kumar S, Clark PM, Shackletnton CH. Cortisol matabolism in human obesity: impaired cortisone →cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999;84:1022-7.
16. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001;281:392-9.
17. Ciaraldi TP, Morales AJ, Hickaman MG, Odom-Ford R, Olefsky JM, Yen SSC. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J Clin Endocrinol Metab 1997;82:1421-5.
18. Lambe KG, Togwood JD. A human peroxisome-proliferator-activated receptor-y is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem 1996;239:1-7.
19. Rosembaum D, Haber RS, Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol 1993;264:E197-202.
20. Bjorntorp P. The origins and consequences of obesity. Diabetes. Ciba Found Symp 1996;201:68-80; discussion 80-9,188-93.
21. Ek I, Arner P, Ryden M. A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin-resistance. Diabetes 2002;51:484-92.
22. Hoffstedt J, Wahremberg H, Thomrne A, Lonnqvist F. The metabolic syndrome is related to beta-3 adrenoreceptor sensitivity in visceral adipose tissue. Diabetologia 1996;39:838-44.
23. Holte J, Bergh T, Berne C, Berglund L, Lithell H. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 1994;78:1052-8.
24. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996;81:2854-64.
25. Grulet H, Hecart AC, Delemer B, Gross A, Sulmont V, Leutenegger M et al. Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome. Clin Endocrinol (Oxf) 1993;38:621-6.
26. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
27. Vettor R, Lombardi AM, Fabris R, Serra R, Pagano C, Macor C et al. Substrate competition and insulin action in animal models. Int J Obes Relat Metab Disord 2000;24Suppl 2:S22-4.
28. Zamorano PL, Mahesh VB, De Sevilla LM, Chorich LP, Bhat GK, Brann DW. Expression and localization of the leptin receptor in endocrine and neuroendocrine tissues of the rat. Neuroendocrinology 1997;65:223-8.
29. Pasquali R, Vicennati V, Gambineri A, Pagotto U. Hormones and pathophysiology of obesity. Eat Weight Disord 2001;6:9-20.
30. Legro RS. The genetics of obesity. Lessons for polycystic ovary syndrome. Ann N Y Acad Sci 2000;900:193-202.
31. Pasquali R, Casimirri F, Vicennati V. Weight control and its beneficial effect on fertility in women with obesity and polycystic ovary syndrome. Hum Reprod 1997;12:82-7.
32. Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996;81:952-60.
33. Lovejoy JC, Bray GA, Bourgeois MO, Macchiavelli R, Rood JC, Greeson C et al. Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 1996;81:2198-203.
34. Holte J. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Bailliers Clin Endocrinol Metab 1996;10:221-47.
35. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995;96:520-7.
36. Dunaif A, Finegood DT. β-cell dysfunction independent of obesity and glucose tolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:2854-64.
37. Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 2001;86:2027-31.
38. Legro RS. Insulin resistance in the polycystic ovary syndrome: treating a phenotype without a genotype. Moll Cell Endocrinol 1998;145:103-10.
39. Achard MC, Thiers MJ. Le virilisme pilaire et son association à l'insuffisance glycolitique (diabète des femmes à barbe). Bull Acad Natl Med 1921;86:51-85.
40. Cibula D, Cifkova R, Fanta M, Poledneivny J, Skibova J. Increased risk of non-insulin diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of polycystic ovary syndrome. Human Reprod 2000;15:785-9.
41. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.
42. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-6.
43. The Expert Committee on the diagnosis and classification of Diabetes Mellitus: report of the Expert Committee on the diagnosis and classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
44. Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynecol Obstet 2001;75:177-84.
45. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 ys. Diabetes 1987;36:523-34.
46. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari C, Pagotto U et al. Impaired glucose tolerance and type 2 diabetes in a large cohort of Mediterranean women with polycystic ovary syndrome: phenotype and predictive factors. Diabetes [In press].
47. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:1017-23.
48. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 2001;86:66-71.
49. Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovary syndrome. J Pediatr 2001;138:38-44.
50. Alford FP, Henriksen JE, Rantzau C, Vaag A, Hew LF, Ward GM et al. Impact of family history of diabetes on the assessment of beta-cell function. Metabolism 1998;47:522-8.
51. Fox R. Prevalence of a positive family history of type 2 diabetes in women with polycystic ovarian disease. Gynaecol Endocrinol 1999;13:390-3.
52. Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993;36:62-7.
53. Chiarelli F, di Ricco L, Mohn A, De Martino M, Verrotti A. Insulin resistance in short children with intrauterine growth retardation. Acta Paediatr Suppl 1999;88:62-5.
54. Phillips DI. Insulin resistance as a programmed response to fetal undernutrition. Diabetologia 1996;39:1119-22.
55. Jaquet D, Gaboriau A, Czernichow P, Levy-Marchal C. Insulin resistance early in adulthood in subjects born with intrauterine growth retardation. J Clin Endocrinol Metab 2000;85:1401-6.
56. Ibanez L, Potau N, Francois I, de Zegher F. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 1998;83:3558-62.
57. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clin Endocrinol (Oxf) 2001;55:667-72.
58. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996;20:291-302.
59. Holmäng A, Larsson BM, Brzezcinska Z, Bjorntorp P. Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol 1992;262:E851-5.
60. Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol 2000;52:81-6.
61. Peppard HR, Iuorno MJ, Marfori J, Nestler JE. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 2001;24:1050-2.
62. Harris MI. Impaired glucose tolerance: prevalence and conversion to NIDDM. Diabet Med 1996;13:S9-11.
63. Ferrannini E, Vichi S, Beck-Nielsen H, Laakso M, Paolisso G, Smith U. Insulin action and age. European Group for the study of Insulin Resistance (EGIR). Diabetes 1996;45:947-53.
64. Pasquali R, Gambineri A, Anconetani B, Vicennati V, Colitta D, Caramelli E et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999;50:517-27.
65. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovary syndrome. Human Reprod 2001;16:1995-8.
66. Pasquali R, Gambineri A. Treatment of the polycystic ovary syndrome with lifestyle intervention. Curr Opin Endocrinol Diabetes 2002;9:459-68.
67. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-74.
68. De Leo V, La Marca A, Petraglia F. Insulin lowering agents in the management of the polycystic ovary syndrome. Endocr Rev 2003;24:633-67.
69. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. Br Med J 2003;327:951-7.
70. Hu BF, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790-7.
71. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.